Ascendis Pharma A / S (Nasdaq: Asnd) is One of the best 52 -week actions to buy, according to analysts. On June 9, Bofa analyst Tazeen Ahmad reiterated a purchase note on action and increased the price of courses to $ 216 from $ 201.
A biopharmaceutical scientist bearing a laboratory blouse, examining a microscope of cells.
The adjustment follows the company providing positive provisional results of the phase 2 trial. The trial has sought to determine the effectiveness of a combined treatment QW Transcon CNP and QW Transcon HGH in children with burstroplasia (ACH). The test results have indicated significant advantages of growth speed announted with combined treatment.
According to the analyst, the test results are favorable and likely to strengthen the company’s prospects to capture market share once treatment has entered the market. Following the positive results of the trial, Ascendis plans to publish 52 -week data of the coach trial in the fourth quarter.
Likewise, the US Food and Drug Administration (FDA) has accepted the new company’s drug request for Transcon, its candidate candidate for the treatment of achondroplasia.
Ascendis Pharma A / S (NASDAQ: ASND) is a biopharmaceutical company that develops and markets new therapies for unsatisfied medical needs, in particular in endocrinology and oncology. It operates a transcond owner’s technological platform to create innovative therapies and potentially the best in class.
Although we recognize the potential of ASnd as an investment, we believe that certain AI actions offer greater upward potential and have a less unknown risk. If you are looking for an extremely undervalued AI stock that should also benefit considerably from the Trump era tariffs and the excessive trend, see our free report on the Best short -term AI stock.
Then read: 10 most popular AI actions to avoid now and the 10 choices of stock of small capitapes of Billionaire David E. Shaw with enormous upward potential.
Disclosure: None.
